- Aptose Biosciences Inc APTO highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies.
- In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mg/m2 over multiple cycles supporting continued dose escalation.
- APTO-253 monomer rapidly transformed to and co-existed with the Fe(253)3 conjugate in peripheral blood.
- Serum levels of APTO-253 and the Fe(253)3 conjugate were dose-proportional, with significantly higher Fe(253)3 conjugate concentrations than monomer.
- In Relapsed or Refractory B-Cell Malignancies, the anti-tumor activity observed in multiple patients, including follicular lymphoma (FL), Waldenstrom’s (WM), Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Tumor reduction in a patient with follicular lymphoma (FL) upon dose escalation from 450 mg to 600 mg.
- IgM reduction in a patient with Waldenstrom’s (WM) at 750mg dose.
- Dose escalation well-tolerated from 150 – 600 mg twice daily over multiple cycles.
- One apparent dose-limiting toxicity of hypertension led to expansion at 750 mg – upon further review appears unlikely related.
- Currently treating patients with B-cell malignancies at 750 mg BID in cohort 5; continued dose escalation planned.
- See the slide presentation here.
- Price Action: APTO shares are down 31.5% at $3.79 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
